340B’s Next Chapter Will Be Won (or Lost) on Data. Most Organizations Aren’t Ready.
By ADAM COHEN The debate over the 340B Drug Pricing Program is complicated. However, beyond the arguments over rebates, contract pharmacies, and program intent sits a simpler reality that every stakeholder should plan around. Whatever form 340B takes next, the value an organization captures will depend on its ability to document and justify every discounted…